Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Vomiting; Nausea; Breast Neoplasms

Treatments: Drug: MK0869, aprepitant / Duration of Treatment: 3 days

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092196

2004_064

0869-071 Extension

Details and patient eligibility

About

The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.

Enrollment: 820 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy.
• Patient must have completed participation in the main study for this protocol.

Exclusion criteria

• Patient has a central nervous system malignancy.
• Patient will receive radiation to the abdomen or pelvis.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)